Intensive care admission of cancer patients: a comparative analysis

Monique M. E. M. Bos1, Ilona W. M. Verburg2, Ineke Dumaij1, Jacqueline Stouthard3, Johannes W. R. Nortier4, Dick Richel5, Eric P.A. van der Zwan2, Nicolette F. de Keizer2 & Evert de Jonge6

1Department of Medicine, Reinier de Graaf Hospital, Delft, The Netherlands
2Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
3Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Dutch Cancer Institute, Amsterdam, The Netherlands
4Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
5Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
6Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands

Keywords
Age differences, cancer, gender differences, intensive care, survival

Abstract
The aim of this study was to obtain insight into which proportion of cancer patients is admitted to an Intensive Care Unit (ICU) and how their survival, demographic, and clinical characteristics relate to cancer patients not admitted to the ICU. Data from patients registered with cancer between 2006 and 2011 in four hospitals in the Netherlands were linked to the Dutch National Intensive Care Evaluation registry. About 36,860 patients with cancer were identified, of whom 2,374 (6.4%) were admitted to the ICU. Fifty-six percent of ICU admissions were after surgery, whereas 44% were for medical reasons. The risk for ICU admission was highest among cancer patients treated with surgery either alone or combined with chemotherapy and/or radiation therapy. Only 80 of 1,073 medical ICU admissions (3.3%) were for cancer-specific reasons. Although more women (54.0%) than men were registered with cancer, the proportion of male cancer patients admitted to an ICU was much higher (9.3 vs. 4.0%, P < 0.001). Five-year survival of cancer patients admitted to the ICU was substantial (41%) although median survival was much lower (1,104 days) than in patients not admitted to the ICU (median survival time not reached, P < 0.001). These results show that one out of 16 cancer patients was admitted to an ICU and that ICU support for this group should not be considered futile.

Introduction
The prognosis of cancer patients has improved due to earlier diagnosis and better therapeutic options [1]. As a consequence of more aggressive therapies, the need of cancer patients for intensive care unit (ICU) support during the course of their disease has increased [2]. Recent data indicate that the outcome of cancer patients on the ICU has improved significantly [3, 4]. ICU admission is now considered appropriate for patients with a malignancy for specified indications such as postoperative care, complications caused by the malignancy and/or its treatment and crises unrelated to the tumor or its therapy [5, 6].

Previous investigations reported on the incidence of cancer and its impact on the outcome in general ICUs [7–9]. These studies showed that a cancer diagnosis on admission to a general ICU is relatively common, varying between 13.5% and 21.5%, and that the outcome of these patients is strongly dependent on the type of admission, with planned surgical and unplanned medical admission types bearing the relatively best and worst prognosis, respectively [7–9].

Although information about the influence of cancer on ICU outcome has become increasingly available during recent years [3, 4, 7–10], knowledge on the proportion and characteristics of cancer patients from a general population that is admitted to an ICU is highly limited. This
information is of considerable interest, not only for insight in epidemiology and health care costs associated with different cancer diagnoses, but also for general and specialist physicians providing treatment and care to patients with a malignancy. The novelty of this study is that it sought to obtain insight into which proportion of cancer patients is admitted to an ICU during the course of their illness and to analyze differences between cancer patients who were and who were not admitted to the ICU with regard to demographics, cancer diagnosis, type of treatment, and outcome. We hypothesized that ICU admissions of cancer patients from a general population would predominantly involve patients undergoing major elective cancer surgery and patients suffering from cancer-and therapy-specific complications, but were not able to predict which percentage of patients with specific cancer and/or treatment types (surgery, chemotherapy, radiation) would be in need of ICU care most. We performed an observational study encompassing a 5-year period and involving 36,860 cancer patients, stratified according to cancer diagnosis and treatment type, in the Netherlands.

Materials and Methods

Patient selection

The primary population consisted of all adult patients with a cancer diagnosis registered between January 1, 2006 and January 1, 2011 in four hospitals in the Netherlands. Two academic hospitals (Academic Medical Center, Amsterdam and Leiden University Medical Center, Leiden) and two community teaching hospitals (Reinier de Graaf Hospital, Delft and Maasstad Hospital, Rotterdam) participated. Patients were selected from the hospital information systems based on encoded “Diagnosis Treatment Combinations” (DTC), a nationwide coding and reimbursement system providing information about the type of care, diagnosis and all treatment modalities specified by the attending physician [11, 12]. A DTC is opened upon first contact with a patient and selected based on specific guidelines [11, 12]. For each patient a DTC remains active as long as he or she receives treatment or is in follow-up for the specified diagnosis. One patient can have more than one DTC, for example in the presence of two different primary tumors. For the current analysis all patients with a DTC related to an oncological diagnosis were included, with the exception of patients with a primary malignancy of the central nervous system (since not all participating hospitals were primary care givers of this type of patients) or superficial skin cancer (since these tumors are not expected to lead to ICU admission or to influence survival). To identify patients who were admitted to an ICU during the study period, data were linked to the database of the Dutch National Intensive Care Evaluation (NICE) registry using a deterministic linkage algorithm [13, 14] using name (encrypted surname and maiden name), date of birth, gender, and the comparison of ICU admission date and start- and end of an cancer period. NICE contains information on all admissions to the ICUs of 84 hospitals in the country (i.e., approximately 90% of all ICUs in the Netherlands) [15, 16]. As such, while the four hospitals from which the primary cancer population was retrieved participated in the NICE registry, ICU admissions of patients from this primary population were also taken into account if they occurred in other hospitals. Within NICE, several measures are taken to improve data quality, including mandatory training in data definitions and data collection and at least three-yearly site-visits with re-collection of data. Data quality in the NICE registry has been evaluated and confirmed published previously [15, 17]. In order to avoid patient identification, identifying variables are included in an encrypted form in NICE. For the current analysis, patient identifying information in the DTC database was encrypted based on the same encryption algorithm as used in NICE. ICU admissions were linked with patients from the primary population in case the DTC encoding cancer was either active or closed less than one year before ICU admission. The date of death was extracted from the hospital information systems. The participating hospitals obtain date of death information from the Dutch population registry. The date of death was updated until the complete follow-up period July 1, 2011. In case a patient is admitted at the ICU and died during the same hospitalization period the date of death is checked using information from the NICE registry.

Ethics

The need for ethical committee approval was waived by the Dutch Central Committee on Research Involving Human Subjects, because the study was purely observational and because only deidentified patient data were used.

Statistical analysis

Samples median test was used to test whether the median age differed for patients with and without ICU admission. Pearson chi-squared test was used to evaluate whether the distribution of the different categories of variables age, gender, phase of active cancer treatment, therapy combination, and type of cancer differed between cancer patients with and without ICU admission. Logistic regression using General Linear Models analyses was used to determine the contribution of the type of cancer on admission to the ICU during an active cancer diagnosis. The calculated odds ratios were adjusted for gender, phase of active cancer treatment, therapy combinations, age, and participating hospital.
For all cancer diagnoses combined a Kaplan–Meier curve was constructed for time to ICU admission. Cumulative percentages after 30, 365, and 730 days of ICU admission were obtained by calculating survival tables for type of cancer and gender. The log rank (Mantel-Cox) test was performed to test whether survival distributions differed between men and women. Time to ICU admission was defined as time from the first day of the first DTC until ICU admission. Patients were censored at one year after the last DTC was closed or at January 1, 2012, whatever came first.

To compare survival after the first diagnosis of cancer between patients with and without ICU admissions during an active cancer diagnosis Kaplan–Meier curves and Cox Proportional Hazard (Cox PH) regression were applied. The starting date of the first DTC was chosen as starting time, date of death was the endpoint. The calculated hazard ratio was adjusted for gender, phase of active cancer treatment, therapy combinations, types of cancer, and age by adding these covariates in the Cox PH regression model. Patients were censored at the end of follow-up period July 1, 2011.

Furthermore, to analyze survival after ICU admission for patients with one or more ICU admissions during an active cancer diagnosis, Kaplan–Meier curves were plotted for different types of cancer and for gender. Patients with a medical admission for cancer; a surgical admission for cancer and other admission diagnoses were compared in Kaplan–Meier curves and the log-rank (Mantel-Cox) test was performed to test whether survival distributions differed. For these analyses ICU admission date of the first ICU admission was chosen as starting time, date of death was the endpoint. Patients were censored at the end of follow-up period July 1, 2011. However, for ICU admissions that took place between July 1, 2011 and January 1, 2012 we used the hospital discharge date or death as endpoint, patients were censored when they survive their hospital stay.

Age was modeled using natural cubic regression splines [18], with four degrees of freedom in both Cox PH regression and logistic regression. The appropriate number of degrees of freedom was assessed by univariate analyses using analysis of variance. The proportional Hazard assumption was tested. For all analyses P-values below 0.05 were considered statistically significant.

All statistical analyses were performed using the statistical environment R version 2.14.1 (Amsterdam, The Netherlands) and PASW statistics 18.

**Results**

**Patients and ICU admissions**

The primary population consisted of 36,860 patients with in total 40,716 cancer diagnoses, indicating that approximately 10% of patients had more than one cancer diagnosis (Table 1). Between January 1, 2006 and January 1, 2011, 2,374 of these patients (6.4%) were admitted at

---

### Table 1. Study population demographics.

|                          | All (% ICU admission) | ICU admission (% within this group) | No ICU admission (% within this group) | P² |
|--------------------------|-----------------------|-------------------------------------|----------------------------------------|----|
| All patients             | 36,860 (6.4)          | 2,374                               | 34,486                                 | <0.001 |
| Total number of cancer diagnosis | 40,716 (6.0)          | 2,458                               | 38,258                                 | <0.001 |
| Age (years), median (interquartile range) | 63 (52–72)            | 66 (57–73)                          | 62 (52–72)                             | <0.001 |
| <45 years                | 5,186 (2.8)           | 143 (6.0)                           | 5,043 (14.6)                           | <0.001 |
| 45–65 years              | 11,063 (5.8)          | 646 (27.2)                          | 10,417 (30.2)                          | <0.001 |
| >60–75 years             | 14,323 (8.1)          | 1,158 (48.8)                        | 13,165 (38.2)                          | <0.001 |
| >75 years                | 6288 (6.8)            | 427 (18.0)                          | 5861 (17.0)                            | 0.214 |
| Gender                   |                       |                                     |                                        |     |
| Male                     | 16,967 (9.3)          | 1,581 (66.6)                        | 15,386 (44.6)                          | <0.001 |
| Female                   | 19,893 (4.0)          | 793 (33.4)                          | 19,100 (55.4)                          | <0.001 |
| Treatment (combinations¹) |                       |                                     |                                        |     |
| Surgery                  | 7,661 (11.8)          | 904 (36.8)                          | 6,757 (17.7)                           | <0.001 |
| Surgery and chemotherapy | 2,044 (9.3)           | 190 (7.7)                           | 1,854 (4.8)                            | <0.001 |
| Surgery and radiation therapy | 1,289 (8.1)          | 104 (4.2)                           | 1,185 (3.1)                            | 0.002 |
| Surgery, chemotherapy, and radiation therapy | 914 (10.5) | 96 (3.9) | 818 (2.1) | <0.001 |
| Chemotherapy             | 3,426 (6.2)           | 213 (8.7)                           | 3,213 (8.4)                            | 0.137 |
| Chemotherapy and radiation therapy | 1,238 (7.0) | 87 (3.5) | 1,151 (3.0) | 0.369 |
| Radiation therapy        | 7,502 (2.3)           | 169 (6.9)                           | 7,333 (19.2)                           | <0.001 |
| Palliative care          | 911 (4.2)             | 38 (1.5)                            | 873 (2.3)                              | 0.017 |
| Other/none               | 15,731 (4.2)          | 657 (26.7)                          | 15,074 (39.4)                          | <0.001 |

¹Combinations of treatments are indicated independent of the order in which these were provided.

²ICU admission versus no ICU admission.
least once to the ICU. Patients admitted to the ICU were older (median age 66 years) than patients not admitted to the ICU (median age 62 years, $P < 0.001$). The proportion of cancer patients admitted to the ICU was highest in the age group 60–75 years (8.1%) and lowest in the age group <45 years (2.8%). The risk of being admitted to an ICU was highest in patients treated with surgery (11.8%), surgery with radiation therapy (8.1%), surgery with chemotherapy (9.3%) and surgery combined with both chemotherapy and radiation therapy (10.5%). A more detailed analysis of the proportions of cancer patients admitted to an ICU by age and cancer therapy is given for specific cancer diagnoses in Tables S1 and S2.

Figure 1 shows the time from the first cancer diagnosis to ICU admission for all patients by Kaplan-Meier curve, revealing that most ICU admissions in cancer patients take place in the first year.

**Different types of malignancy**

The most frequent types of malignancy in the primary population were breast cancer (20.2% of all cancer diagnoses), hematological malignancy (10.5%), lung cancer (8.7%), colorectal carcinoma (8.3%), and prostate cancer (7.2%) (Table 2). Esophageal cancer most commonly lead to ICU admission (27.3% of patients with this diagnosis were admitted within 730 days, Table 2); In Table S3, the odds ratios for ICU admission are given for specific cancer diagnoses after adjustment for gender, cancer treatment, and age. In accordance, esophageal cancer was after adjustment still associated with the highest odds ratio (3.27) compared with lung cancer. Patients with other types of gastrointestinal cancer, including colorectal (10.4%) and pancreatic and biliary cancer (9.4%) also were relatively frequently admitted to the ICU (Table 2).

**Indications for ICU admissions**

According to the APACHE IV ICU admission diagnoses, 56.2% of ICU admissions were surgical. Only 26.9% of ICU admissions were directly linked with cancer (Table 3). About 23.6% of all ICU admissions of patients were after surgery for cancer, whereas 32.6% of admissions were associated with surgery not directly related to the cancer diagnosis. Almost half of admissions to the ICU was for nonsurgical reasons. Only 3.3% of ICU admissions were medical and directly linked with cancer; the majority of medical admissions was because of infection and sepsis (18.5% of all ICU admissions of cancer patients).

**Gender differences**

The primary population of cancer patients comprised more women (54.0%) than men (Table 1). In contrast, in the ICU group the proportion of men was much higher (66.6%, vs. 44.6% men in the non-ICU group, $P < 0.001$). This gender difference with more men than women admitted to the ICU was present in all cancer diagnosis-specific subgroups, although differences for esophageal cancer and melanoma and ‘other types of cancer’ did not reach statistical significance (Table 2).

**Mortality**

Figure 2 shows 5-year mortality stratified according to ICU admission status. Clearly, patients who were admitted to the ICU had a strongly reduced survival (median survival time 1104 days) when compared with patients who were not admitted to the ICU (median survival time not reached during the observation period; $P < 0.001$). Amongst cancer patients admitted to the ICU median survival times were 789 days for men and 574 days for women (not significant). Figure 3A–J shows survival of patients admitted to the ICU stratified according to cancer diagnosis. Median survival times were relatively long for prostate cancer and breast cancer (not reached within 5 years) and esophageal cancer (1,328 days), and relatively short for hematological malignancies (139 days). Figure 4 shows survival of patients admitted to an ICU coded as
Table 2. Cumulative intensive care unit admission stratified according to cancer diagnosis and gender.

| Nongender-specific malignancy                  | Number | 30 days ICU admission (%) | 365 days ICU admission (%) | 730 days ICU admission (%) |
|----------------------------------------------|--------|---------------------------|-----------------------------|----------------------------|
|                                             | N (%)  | All | Male | Female | All | Male | Female | All | Male | Female | P     |
| Lung cancer                                  | 3,546  | 1,421 | 2,125 | 1,6 | 0.047 | 5.3 | 6.2 | 4.0 | 0.061 | 6.3 | 7.5 | 4.4 | 0.003 |
| Head and neck cancer                         | 1,876  | 859  | 1,017 | 0.9 | 0.76 | 3.7 | 4.7 | 2.6 | 0.131 | 5.2 | 6.6 | 3.5 | 0.001 |
| Colorectal cancer                            | 3,389  | 1,572 | 1,817 | 2.3 | 0.66 | 8.4 | 9.9 | 6.7 | 0.263 | 10.4 | 11.9 | 8.7 | 0.003 |
| Pancreatic and biliary cancer                | 2,759  | 1,341 | 1,418 | 2.8 | 0.032 | 8.2 | 9.9 | 6.3 | 0.066 | 9.4 | 11.1 | 7.6 | 0.005 |
| Esophageal cancer                            | 1,661  | 414  | 1,274 | 2.4 | 0.67 | 25.5 | 26.7 | 22.0 | 0.214 | 27.3 | 28.7 | 23.1 | 0.102 |
| Other types of GI-cancer                     | 1,323  | 520  | 803   | 2.5 | 0.37 | 10.4 | 11.7 | 8.5 | 0.382 | 11.8 | 13.7 | 9.0 | 0.111 |
| Urinary tract cancer                         | 2,367  | 755  | 1,612 | 0.9 | 0.45 | 4.6 | 5.1 | 3.4 | 0.547 | 5.5 | 6.2 | 4.1 | 0.111 |
| Melanoma                                     | 491    | 122  | 379   | 0.2 | 0.78 | 0.8 | 1.8 | 0.0 | 0.050 | 1.5 | 2.5 | 0.7 | 0.059 |
| Sarcomas                                     | 2,245  | 1,086 | 1,149 | 0.4 | 0.17 | 1.9 | 2.3 | 1.4 | 0.017 | 2.8 | 3.6 | 1.9 | 0.019 |
| Hematological malignancy                     | 4,275  | 1,905 | 2,370 | 1.6 | 0.67 | 4.7 | 5.8 | 3.3 | 0.332 | 6.2 | 7.7 | 4.4 | <0.001 |
| Other types of cancer                        | 2,162  | 1,114 | 1,048 | 1.4 | 0.29 | 3.3 | 4.0 | 2.6 | 0.193 | 4.2 | 5.4 | 3.0 | 0.201 |

| Gender-specific malignancy                   | Number | 30 days ICU admission (%) | 365 days ICU admission (%) | 730 days ICU admission (%) |
|----------------------------------------------|--------|---------------------------|-----------------------------|----------------------------|
|                                             | N (%)  | All | Male | Female | All | Male | Female | All | Male | Female | P     |
| Breast cancer                                | 8,241  | 20.2 | 1,048 | 1,114 | 1.4 | 0.293 | 3.3 | 4.0 | 2.6 | 0.193 | 4.2 | 5.4 | 3.0 | 0.201 |
| Ovarian and endometrial cancer               | 1,598  | 8.9 | 1,015 | 1,015 | 0.0 | 0.293 | 3.3 | 4.0 | 2.6 | 0.193 | 4.2 | 5.4 | 3.0 | 0.201 |
| Cervical cancer                              | 446    | 11.1 | 446   | 446   | 0.0 | 0.293 | 3.3 | 4.0 | 2.6 | 0.193 | 4.2 | 5.4 | 3.0 | 0.201 |
| Testicular cancer                            | 395    | 1.0 | 395   | 395   | 0.0 | 0.293 | 3.3 | 4.0 | 2.6 | 0.193 | 4.2 | 5.4 | 3.0 | 0.201 |

1Percentage of all cancer diagnoses.
2Percentage of type of cancer in this cohort of 40,716 cancer diagnoses.
3No comparison analysis is performed because the factor variable has only one value for every stratum.
medical admission for cancer; surgical admission for cancer; or other admission diagnosis. The survival curves did not significantly differ.

**Discussion**

To the best of our knowledge, our study is the first to report on the proportion of cancer patients from the general population that is admitted to an ICU during the course of their illness, stratified according to cancer diagnosis and type of treatment. Of 36,860 patients registered in four hospitals with at least one cancer diagnosis 6.4% was admitted to the ICU. Surgery was the most common treatment associated with ICU admission: of all cancers treated with surgery solely or in combination with other modalities 10.9% required ICU care. Among different cancer diagnoses, patients with esophageal cancer entered the ICU most frequently (27.3%).

Previous studies have documented that most ICU admissions of cancer patients involve postoperative care after elective surgery [14, 19, 20]. Accordingly, our data show that the majority of cancer patients entered the ICU during the course of their disease because of surgical treatment. Of interest, however, of all cancer patients who were admitted to the ICU for surgical reasons, only 41.9% of cases involved surgical treatment directly related to cancer. Hence, more than half of cases were related to surgical interventions not directly linked with the primary cancer diagnosis, most notably gastrointestinal and cardiovascular surgery. In accordance with previous investigations [9, 21–23], infection and sepsis were the most common indications for admission in medical cancer patients.

Although in this population of cancer patients women were more prevalent than men, the proportion of men that entered the ICU was more than twice as large when compared with women. While for the overall population this gender difference can be partly explained by the high prevalence of breast cancer (which very rarely results in ICU admission), men more often entered the ICU across all cancer diagnoses. Previous studies also indicated that men are more likely to receive ICU care [24–27]. A large population-based study conducted in Canada demonstrated that older women with critical illness were less likely than critically ill men to be admitted to an ICU [26]. Similarly, a prospective study involving 25,998 adult patients admitted to 31 ICUs in Austria documented gender-related differences in ICU care, with male patients—despite presenting with a lower severity of illness—more likely than female patients to receive a high level of care, as defined by the number of invasive procedures [25]. Although in that investigation women had a higher observed mortality rate than men, there was no difference in outcome after adjustment for the severity of illness [25]. Overall ICU mortality did not differ between sexes in another study [28]. Our current study extends these

| Type of ICU admission based on APACHE IV | Number of patients (%) |
|-----------------------------------------|------------------------|
| Surgery for cancer                       | 579 (23.6)             |
| Other types of surgery                   |                        |
| Gastro-intestinal surgery               | 322 (13.1)             |
| Respiratory tract surgery (other than cancer) | 163 (6.6)           |
| Cardiovascular surgery                   | 196 (8.0)              |
| Other                                    | 121 (4.9)              |
| Medical cancer                           | 80 (3.3)               |
| Other types of nonsurgical admissions    |                        |
| Cardiac                                  | 173 (7.0)              |
| Respiratory                              | 143 (5.8)              |
| Infection/Sepsis                         | 455 (18.5)             |
| Thrombosis/hemorrhage                    | 91 (3.7)               |
| Neurological                             | 44 (1.8)               |
| Other nonsurgical causes for ICU admission| 87 (3.5)              |
| Missing                                  | 4 (0.2)                |

*Table 3. Reason for admission in the ICU.*

![Figure 2](image_url). Survival of cancer patients who were or were not admitted to the ICU. Survival of cancer patients who were (solid line) or who were not (dotted line) admitted to the ICU. This analysis encompassed 36,860 adult patients registered with a cancer diagnosis between January 1, 2006 and January 1, 2011 in four hospitals in the Netherlands. Of these patients, 2374 were admitted to the ICU during the study period. The graph shows Kaplan–Meier curves starting at the date of cancer diagnosis registration; p value indicates the difference between groups.
ICU Admissions of Cancer Patients

M. M. E. M. Bos et al.

A Lung cancer
Survival
30 days 0.82
365 days 0.64
730 days 0.53
50% 1,063 days

B Head and neck cancer
Survival
30 days 0.82
365 days 0.58
730 days 0.51
50% 700 days

C Colorectal cancer
Survival
30 days 0.80
365 days 0.62
730 days 0.49
50% 700 days

D Pancreatic and biliary cancer
Survival
30 days 0.82
365 days 0.56
730 days 0.47
50% 505 days

E Esophageal cancer
Survival
30 days 0.93
365 days 0.72
730 days 0.60
50% 1,328 days

Figure 3. Kaplan–Meier survival curves of cancer patients admitted to the ICU according to type of cancer. (A) Lung cancer, (B) Head and neck cancer, (C) Colorectal cancer, (D) Pancreatic and biliary cancer, (E) Esophageal cancer, (F) Other types of gastrointestinal cancer, (G) Urinary tract cancer, (H) Hematological malignancy, (I) Breast cancer, (J) Prostate cancer.

data by showing that long-term survival of cancer patients admitted to the ICU does not differ between men and women. At present it is unclear what drives the apparent gender difference with regard to ICU admission of cancer patients, although some studies have suggested that males have more comorbid conditions at the point of cancer diagnosis, which may drive more frequent ICU admission [29–32].

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
More than 60% of cancer patients have an expected survival beyond 5 years [1, 33], illustrating the need to study long-term outcome in patients with a malignancy. Previous studies of long-term survival of ICU patients have suggested an increase in mortality during several years after hospital discharge when compared with an age- and gender-matched population [34, 35]. Among different diagnoses, cancer patients had the greatest relative risk of mortality (more than threefold) during 5 years after hospital discharge following ICU admission in a cohort of 12,180 ICU patients from 25 hospitals in Finland [35]. In accordance, the presence of a new
malignancy was associated with a high risk of death within the first year after discharge (hazard ration 4.60) in a single-center study conducted in Australia comprising almost 20,000 ICU patients who survived to discharge [36]. A more recent study conducted in the Netherlands analyzed mortality up to 3 years after hospital discharge of patients who had received ICU care. Whereas 1- and 3-year mortalities after hospital discharge were 12.5% and 27.5% respectively for the total ICU population, in cancer patients mortality was almost twice as high at both time points [14]; these data are in line with our current long-term survival data of cancer patients after ICU admission. We also analyzed mortality up to 5 years after ICU admission stratified according to cancer diagnosis. Of note, 5-year survival rates of this subgroup of patients admitted to the ICU for their cancer were consistently higher than 5-year survival rates reported for these cancer diagnoses in the Dutch population, that is, 13% for esophageal cancer, 57% for colorectal cancer, 4% for pancreatic cancer, 8% for biliary cancer, and 13% for lung cancer [37]. Although these data cannot be compared directly, they support that ICU admission involves a selection of patients with relatively favorable therapeutic perspectives, for example because major surgery requiring postoperative ICU care will be limited to patients with early stage solid tumors carrying the better prognosis. The difference with long-term outcome with the general cancer population may even be higher considering that 5-year survival rate reported here relates to ICU admission date and not to date of cancer diagnosis. The finding that in our overall population cancer patients who were not admitted to the ICU did much better than patients who were admitted to the ICU (Fig. 2A) can be explained by the fact that large patient groups with certain cancer diagnoses, such as breast and prostate cancer, have a relatively favorable prognosis and are rarely admitted to the ICU (Table 2).

A limitation of our and previous studies that addressed long-term outcome after ICU admission [14, 34–36] is that causes of death after hospital discharge were not specified and may be unrelated to ICU admission or cancer diagnosis. In addition, since 90% of all ICUs participate in the NICE registry we may have missed ICU referrals of some patients enrolled in our general population. The first day of the first DTC was used as starting time to determine time to ICU admission and death. In patients with more than one cancer diagnosis it would have been optimal to use the most relevant DTC for these calculations; however, it is not possible to retrieve this information from the DTC registry in a reliable manner. Additional limitations include the absence of information regarding severity scores in patients admitted to the ICU and cancer staging in the study population. Finally, it is uncertain whether the results, which were derived from four hospitals, are representative for the general population.

In conclusion, we report detailed information on the subgroup of cancer patients admitted to an ICU during a 5-year study period, comparing their demographics, diagnoses, and type of therapy with those in patients from the same population who did not receive ICU care. Our main findings were that only 6.4% of cancer patients were admitted to the ICU, that 26.9% of all ICU admissions of cancer patients were related to their cancer diagnosis, that most ICU admissions were after surgery and within one year after discharge, and that cancer patients admitted to the ICU had a consistently higher 5-year survival rate compared to the Dutch general cancer population.

Figure 4. Survival of patients admitted to an ICU coded as medical admission for cancer, surgical admission for cancer, or other admission diagnosis.
year of cancer diagnosis, and that in particular a diagnosis of gastrointestinal cancer was associated with ICU admission. The primary intent of our descriptive survey was not to change health care policies, but rather to provide epidemiologic data on cancer patients under treatment in general hospitals who during the course of their disease do or do not need ICU care. Patients with gastrointestinal malignancies, most notably esophageal cancer, were most often admitted to the ICU. In accordance, most patients entered the ICU for postoperative care. Considering the improved prognosis of cancer patients in general, combined with improved care on ICUs in general, surveys like presented here are temporal and likely to change at least in part depending on tumor type. Up-to-date knowledge of the outcome of cancer patients in relation to their need for ICU care can influence the discussion between and decision making by cancer specialists and intensivists.

**Conflict of Interest**

None declared.

**References**

1. Brenner, H. 2002. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131–1135.
2. Azoulay, E., M. Soares, M. Darmon, D. Benoit, S. Pastores, and B. Afessa. 2011. Intensive care of the cancer patient: recent achievements and remaining challenges. Ann. Intensive Care 1:5.
3. De Jonge, E., and M. M. Bos. 2009. Patients with cancer on the ICU: the times they are changing. Crit. Care 13:122.
4. Darmon, M., and E. Azoulay. 2009. Critical care management of cancer patients: cause for optimism and need for objectivity. Curr. Opin. Oncol. 21:318–326.
5. Groeger, J. S., and R. N. Aurora. 2001. Intensive care, mechanical ventilation, dialysis, and cardiopulmonary resuscitation. Implications for the patient with cancer. Crit. Care Clin. 17:791–803.
6. Staudinger, T., B. Stoiser, M. Mullner, G. J. Locker, K. Laczika, S. Knapp, et al. 2000. Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit. Care Med. 28:1322–1328.
7. Tacccone, F. S., A. A. Artigas, C. L. Sprung, R. Moreno, Y. Sakr, and J. L. Vincent. 2009. Characteristics and outcomes of cancer patients in European ICUs. Crit. Care 13:R15.
8. Soares, M., P. Caruso, E. Silva, J. M. Teles, S. M. Lobo, G. Friedman, et al. 2010. Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit. Care Med. 38:9–15.
9. Bos, M. M., N. F. de Keizer, I. A. Meynaar, F. Bakhshi-Raiez, and E. de Jonge. 2012. Outcomes of cancer patients after unplanned admission to general intensive care units. Acta Oncol. 51:897–905.
10. Maschmeyer, G., F. L. Bertschat, K. T. Moesta, E. Hausler, T. K. Held, M. Nolte, et al. 2003. Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. Eur. J. Cancer 39:783–792.
11. Available at www.nza.nl/zorgonderwerpen/dossiers/dbc-dossier/ (accessed March 2011).
12. Hasaart, F. 2011. Incentives in the diagnosis treatment combination payment system for specialist medical care. Academic thesis, University of Maastricht University Press Maastricht.
13. Roos, L. L., and A. Wajda. 1991. Record linkage strategies. Part I: Estimating information and evaluating approaches. Methods Inf. Med. 30:117–123.
14. Brinkman, S., E. de Jonge, A. Abu-Hanna, M. S. Arbous, D. W. de Lange, and N. F. de Keizer. 2013. Mortality after hospital discharge in ICU patients. Crit. Care Med. 41:1229–1236.
15. Arts, D., N. de Keizer, G. J. Scheffer, and E. de Jonge. 2002. Quality of data collected for severity of illness scores in the Dutch National Intensive Care Evaluation (NICE) registry. Intensive Care Med. 28:656–659.
16. Brinkman, S., A. Abu-Hanna, A. van der Veen, E. de Jonge, and N. F. de Keizer. 2012. A comparison of the performance of a model based on administrative data and a model based on clinical data: effect of severity of illness on standardized mortality ratios of intensive care units. Crit. Care Med. 40:373–378.
17. Koetsier, A., N. Peek, E. de Jonge, D. Dongelma, G. van Berkel, and N. de Keizer. 2013. Reliability of in-hospital mortality as a quality indicator in clinical quality registries. A case study in an intensive care quality register. Methods Inf. Med. 52:432–440.
18. Hastei, T., R. Tibshirani, and J. Friedman. Basic expansions and regularization. The elements of statistical learning: data mining, inference, and prediction 2001: 115–163.
19. Rhodes, A., R. P. Moreno, B. Metnitz, H. Hochrieser, P. Bauer, and P. Metnitz. 2011. Epidemiology and outcome following post-surgical admission to critical care. Intensive Care Med. 37:1466–1472.
20. Bos, M. E. M. M., F. Bakhshi-Raiez, J. W. T. Dekker, de Keizer N. F., and de Jonge E.. 2013. Outcomes of intensive care unit admissions after elective cancer surgery. Eur. J. Surg. Oncol. 39:548–592. (In press).
21. Benoit, D. D., K. H. Vandewoude, J. M. Decruyenaere, E. A. Hoste, and F. A. Colardyn. 2003. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit. Care Med. 31:104–112.
22. Darmon, M., G. Thiery, M. Ciroldi, S. de Miranda, L. Galicier, E. Raffoux, et al. 2005. Intensive care in patients with newly diagnosed malignancies and a
need for cancer chemotherapy. Crit. Care Med. 33:2488–2493.
23. Thiery, G., E. Azoulay, M. Darmon, M. Ciroldi, S. De Miranda, V. Levy, et al. 2005. Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J. Clin. Oncol. 23:4406–4413.
24. Keenan, S. P., P. Dodek, K. Chan, R. S. Hogg, K. J. Craib, A. H. Anis, et al. 2002. Intensive care unit admission has minimal impact on long-term mortality. Crit. Care Med. 30:501–507.
25. Valetin, A., B. Jordan, T. Lang, M. Hiesmayr, and P. G. Metnitz. 2003. Gender-related differences in intensive care: a multiple-center cohort study of therapeutic interventions and outcome in critically ill patients. Crit. Care Med. 31:1901–1907.
26. Fowler, R. A., N. Sabur, P. Li, D. N. Juurlink, R. Pinto, M. A. Hladunewich, et al. 2007. Sex- and age-based differences in the delivery and outcomes of critical care. CMAJ 177:1513–1519.
27. Reade, M. C., S. Yende, and D. C. Angus. 2011. Revisiting mars and venus: understanding gender differences in critical illness. Crit. Care 15:180.
28. Nachtigall, I., S. Tafelski, A. Rothbart, L. Kaufner, M. Schmidt, A. Tamarkin, et al. 2011. Gender-related outcome difference is related to course of sepsis on mixed ICUs: a prospective, observational clinical study. Crit. Care 15:R151.
29. Koppert, L. B., M. L. Janssen-Heijnen, M. W. Louwman, V. E. Lemmens, B. P. Wijnhoven, H. W. Tilanus, et al. 2004. Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients: a population-based study. Eur. J. Gastroenterol. Hepatol. 16:681–688.
30. Janssen-Heijnen, M. L., S. Houterman, V. E. Lemmens, M. W. Louwman, H. A. Maas, and J. W. Goebert. 2005. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit. Rev. Oncol. Hematol. 55:231–240.
31. Asmis, T. R., K. Ding, L. Seymour, F. A. Shepherd, N. B. Leighl, T. L. Winton, et al. 2008. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J. Clin. Oncol. 26:54–59.
32. Dent, O. F., P. H. Chapuis, A. A. Renwick, and E. L. Bokey. 2009. The importance of tumor stage and relative survival analysis for the association between sex and survival after resection of colorectal cancer. Ann. Surg. 249:402–408.
33. Ganz, P. A., J. Casillas, and E. E. Hahn. 2008. Ensuring quality care for cancer survivors: implementing the survivorship care plan. Semin. Oncol. Nurs. 24:208–217.
34. Ridley, S., and L. Plenderleith. 1994. Survival after intensive care. Comparison with a matched normal population as an indicator of effectiveness. Anaesthesia 49:933–935.
35. Niskanen, M., A. Kari, and P. Halonen. 1996. Five-year survival after intensive care–comparison of 12,180 patients with the general population. Finnish ICU Study Group. Crit. Care Med. 24:1962–1967.
36. Williams, T. A., G. J. Dobb, J. C. Finn, M. W. Knuiman, E. Geelhoed, K. Y. Lee, et al. 2008. Determinants of long-term survival after intensive care. Crit. Care Med. 36:1523–1530.
37. TNCR. Available at http://www.cijfersoverkanker.nl (accessed June 2012).

Supporting Information

Additional Supporting Information may be found in the online version of this article:
Table S1. Cumulative intensive care unit admission for the different age groups.
Table S2. Cumulative intensive care unit admissions according to cancer diagnosis and type of treatment.
Table S3. Logistic regression for ICU admission for different types of cancer.